Art. 28 Directive (EU) 2001/83

In forcesince 26 Jan 2007cited 47×
1.

With a view to the granting of a marketing authorisation for a medicinal product in more than one Member State, an applicant shall submit an application based on an identical dossier in these Member States. The dossier shall contain the information and documents referred to in Articles 8, 10, 10a, 10b, 10c and 11. The documents submitted shall include a list of Member States concerned by the application.

The applicant shall request one Member State to act as ‘reference Member State’ and to prepare an assessment report on the medicinal product in accordance with paragraphs 2 or 3.

2.

Where the medicinal product has already received a marketing authorisation at the time of application, the concerned Member States shall recognise the marketing authorisation granted by the reference Member State. To this end, the marketing authorisation holder shall request the reference Member State either to prepare an assessment report on the medicinal product or, if necessary, to update any existing assessment report. The reference Member State shall prepare or update the assessment report within 90 days of receipt of a valid application. The assessment report together with the approved summary of product characteristics, labelling and package leaflet shall be sent to the concerned Member States and to the applicant.

3.

In cases where the medicinal product has not received a marketing authorisation at the time of application, the applicant shall request the reference Member State to prepare a draft assessment report, a draft summary of product characteristics and a draft of the labelling and package leaflet. The reference Member State shall prepare these draft documents within 120 days after receipt of a valid application and shall send them to the concerned Member States and to the applicant.

4.

Within 90 days of receipt of the documents referred to in paragraphs 2 and 3, the Member States concerned shall approve the assessment report, the summary of product characteristics and the labelling and package leaflet and shall inform the reference Member State accordingly. The reference Member State shall record the agreement of all parties, close the procedure and inform the applicant accordingly.

5.

Each Member State in which an application has been submitted in accordance with paragraph 1 shall adopt a decision in conformity with the approved assessment report, the summary of product characteristics and the labelling and package leaflet as approved, within 30 days after acknowledgement of the agreement.

The 10 that are cited most themselves, of 47.

  • Directive (EU) 2004/27Lawamends

  • Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination o…3Law

    … компетентният орган на референтната държава членка, посочена в член 28 от Директива 2001/83/ЕО („референтната държава членка“), след …

  • Judgment of the Court (First Chamber) of 16 October 2008. The Queen, on the application of Synthon BV v Licensing Authority of the DepartmenDecisioninterprets

    This reference for a preliminary ruling concerns the interpretation of Article 28 of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use …

    16 Oct 2008 · 62006CJ0452

  • Judgment of the Court (Second Chamber) of 14 March 2018. Proceedings brought by Astellas Pharma GmbH.Decisioninterprets

    This request for a preliminary ruling concerns the interpretation of Articles 28 and 29 of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human …

    14 Mar 2018 · 62016CJ0557

  • Commission Regulation (EU) No 712/2012 of 3 August 2012 amending Regulation (EC) No 1234…1Law

    … държава членка, посочена в член 32 от Директива 2001/82/ЕО и член 28 от Директива 2001/83/ЕО (наричана по-долу „референтната държава …

  • Arzneimittelgesetz1618aLaw

    … Name und Anschrift des Herstellers, 15. bei Genehmigung des Arzneimittels nach den Artikeln 28 bis 39 der Richtlinie 2001/83/EG, in der Fassung der Richtlinien 2004/24/EG und 2004/27/EG, mit verschiedenen Namen in den betroffenen …

  • Gesetz über den Verkehr mit Arzneimitteln112225b27Law

    … bei einem Arzneimittel, das unter anderen Bezeichnungen in anderen Mitgliedstaaten der Europäischen Union nach den Artikeln 28 bis 39 der Richtlinie 2001/83/EG für das Inverkehrbringen genehmigt ist, ein Verzeichnis der in den einzelnen …

  • Judgment of the Court (First Chamber) of 18 June 2009. The Queen, on the application of Generics (UK) Ltd v Licensing Authority.Decision

    Article 28(1) of Directive 2001/83 states: ‘With a view to the granting of a marketing authorisation for a medicinal product in more than one Member State, an applicant shall submit an application based on an identical dossier in these …

    18 Jun 2009 · 62007CJ0527

  • Arrêt du Tribunal (septième chambre) du 11 juin 2015. Laboratoires CTRS contre Commission européenne.Decision

    … authorisations in accordance with the procedures for mutual recognition laid down in Articles [17 and 18 or in Article 28(4) of Directive 2001/83/EC], and without prejudice to intellectual property law or any other provision of Community …

    11 Jun 2015 · 62014TJ0452

  • Opinion of Advocate General Bobek delivered on 7 December 2017. Proceedings brought by Astellas Pharma GmbH.Decision

    However, there are two replies to this objection, apart from the basic fact of absence of better alternatives. First, that it is simply the necessary consequence of having a decentralised system under Article 28 of Directive 2001/83. It is …

    7 Dec 2017 · 62016CC0557